Press release
Leading Element Driving Change in the Peptide Based Metabolic Disorders Therapeutics Market in 2025: Obesity Rise Driving Growth In Peptide-Based Metabolic Disorders Therapeutics Driver
Peptide Based Metabolic Disorders Therapeutics Market Growth
The market size for peptide-based metabolic disorder therapeutics has seen significant progress in recent years, projecting an expansion from $29.89 billion in 2024 to $34.4 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. The historical progression of this industry can be attributed to factors like rising prevalence of metabolic diseases, advancements in peptide synthesis procedures, an increase in health care expenses, the surge in older population, growth in the biopharmaceutical sector, newly approved regulatory therapies, and a greater understanding and awareness concerning personalized medicine.
Over the coming years, the market for peptide-based metabolic disorders therapeutics is anticipated to witness a significant surge, reaching $59.85 billion in 2029 and exhibiting a compound annual growth rate (CAGR) of 14.8%. This market growth during the forecast period is linked to factors such as the creation of new peptide analogs, increased R&D funding for metabolic disorders, the application of precision medicine, growth of emerging markets, joint ventures and partnerships in drug creation, enhancement of delivery technologies, and a patient-centric therapy focus. The forecast period will likely see trends like the application of artificial intelligence in drug research, growth of tailored treatments, use of CRISPR/Cas9 in genetic therapies, the use of wearable tech for patient monitoring, the creation of oral peptide compositions, the emerging importance of digital therapeutics in disease control, and enlargement of bio-banking for personalized treatments.
What Is Contributing to the Growth of the Peptide Based Metabolic Disorders Therapeutics Market?
The peptide-based metabolic disorders therapeutic market's growth is anticipated to be fueled by the mounting cases of obesity. Characterised by an excessive accumulation of body fat, obesity is a medical condition that presents serious health risks. The surge in obesity cases can be attributed to inactive lifestyles, poor diet habits, genetic predisposition, and environment factors that encourage high-calorie diets and lack of physical activity. Therapeutics for peptide-based metabolic disorders target conditions such as obesity by utilizing peptides to manage metabolic functions, enhance insulin sensitivity, and monitor appetite. This contributes to better health results for patients and decreases the long-term health hazards associated with these chronic conditions. For example, The British Diabetic Association reported in April 2024 that there are 4.4 million diabetes patients in the UK, and an additional 1.2 million people potentially have undiagnosed type 2 diabetes. The registration figures for 2022-23 show a rise of 167,822 from the previous year. Consequently, the escalating prevalence of obesity is steering the growth of the peptide-based metabolic disorder therapeutics market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Who Are the Dominant Companies Influencing Peptide Based Metabolic Disorders Therapeutics Market Trends?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
How Is the Peptide Based Metabolic Disorders Therapeutics Market Evolving?
Leading firms in the peptide-based metabolic disorders therapeutics market are creating novel therapies, including anti-diabetic biosimilars, to cater to unmet healthcare needs and broaden treatment options for patients. Anti-diabetic biosimilars, which are peptide-based, provide therapy options that mirror existing treatments for diabetes. These offer similar efficacy and safety compared to well-known medications, and also have the potential to reduce treatment expenses by adopting competitive pricing approaches. As an example, in January 2024, Lirafit was launched by Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical corporation. This biosimilar of Liraglutide, a widely used anti-diabetic medication, has been introduced in India. It is part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) family. Drugs in this class simulate the natural GLP-1 hormone's actions, fundamental for blood sugar regulation. Clinical trials have tested this biosimilar and confirmed its efficacy in reducing glycemic indicators, facilitating weight loss, and raising cardiovascular safety. These factors are essential in the control of diabetes and concomitant conditions, such as obesity and cardiovascular diseases.
What Are the Different Segmentations in the Peptide Based Metabolic Disorders Therapeutics Market?
The peptide based metabolic disorders therapeutics market covered in this report is segmented -
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report
Which Region Is at the Forefront of the Peptide Based Metabolic Disorders Therapeutics Market?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The Peptide Based Metabolic Disorders Therapeutics Global Market Report?
- Market Size Analysis: Analyze the Peptide Based Metabolic Disorders Therapeutics Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Peptide Based Metabolic Disorders Therapeutics Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Peptide Based Metabolic Disorders Therapeutics Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Peptide Based Metabolic Disorders Therapeutics Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16764
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Element Driving Change in the Peptide Based Metabolic Disorders Therapeutics Market in 2025: Obesity Rise Driving Growth In Peptide-Based Metabolic Disorders Therapeutics Driver here
News-ID: 3864097 • Views: …
More Releases from The Business Research Company
Global Organometallics Market Expansion at 5.8% CAGR, Valued at $3.93 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
What Are the Organometallics Market Size Forecast for 2025?
In recent years, the organometallics market has seen a robust growth. The market value is projected to rise from $2.98 billion in 2024 to $3.14 billion in 2025, marking a compound annual growth rate (CAGR) of 5.4%. Several factors have propelled…
Medical Isotopes Market on Path to Hit $9.5 Billion by 2029 at 7% CAGR
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Medical Isotopes Market Outlook: What Size And CAGR Are Anticipated By 2025?
The market size for medical isotopes has seen robust growth in the past few years. It's projected to expand from $6.8 billion in 2024 to $7.26 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%.…
Future of Homogeneous Precious Metal Catalyst Market: Size, Share & Forecasts to …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Homogeneous Precious Metal Catalyst Market by 2025?
The market size of the uniform precious metal catalyst has seen a swift expansion in the recent past. Its growth is projected to leap from $2.65 billion in 2024 to $2.94 billion in 2025, exhibiting…
Gamma Oryzanol Market Size to Reach $2.37 Billion by 2029 | Growth at 6.1% CAGR …
"Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Gamma Oryzanol Industry?
In recent times, the market size of gamma oryzanol has significantly increased. It is projected to expand from $1.77 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. This growth can be…
More Releases for Peptide
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market …
Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).
[https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
